WO2010094906A1 - Stabilisation des proteines - Google Patents

Stabilisation des proteines Download PDF

Info

Publication number
WO2010094906A1
WO2010094906A1 PCT/GB2009/050867 GB2009050867W WO2010094906A1 WO 2010094906 A1 WO2010094906 A1 WO 2010094906A1 GB 2009050867 W GB2009050867 W GB 2009050867W WO 2010094906 A1 WO2010094906 A1 WO 2010094906A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
aqueous composition
dry
drying
dry composition
Prior art date
Application number
PCT/GB2009/050867
Other languages
English (en)
Inventor
Jan Jezek
Charles Potter
Original Assignee
Arecor Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Limited filed Critical Arecor Limited
Priority to CA2726230A priority Critical patent/CA2726230A1/fr
Priority to PCT/GB2009/050867 priority patent/WO2010094906A1/fr
Priority to EP20090785343 priority patent/EP2341940A1/fr
Priority to US12/851,328 priority patent/US20110033549A1/en
Publication of WO2010094906A1 publication Critical patent/WO2010094906A1/fr
Priority to US13/917,937 priority patent/US20130280229A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to the stability of proteins, particularly the stability of proteins in solid state, e.g. in frozen condition or following partial or substantial removal of water such as by drying or freeze-drying.
  • proteins e.g., enzymes, antibodies or therapeutic proteins are unstable and are susceptible to structural degradation and consequent loss of activity while stored.
  • the processes involved in protein degradation can be divided into physical (i.e. processes affecting non-covalent interactions, such as loss of quaternary, tertiary or secondary structure, aggregation, surface adsorption) and chemical (i.e. processes involving a covalent change such as de-amidation, oxidation, disulphide scrambling etc.).
  • the rates of the degradation processes are proportional to temperature. Proteins are consequently generally more stable at lower temperatures.
  • a typical lyophilised commercial protein formulation always comprises a buffer, such as phosphate buffer, and one or more additives.
  • the additives may include one or more of the following:
  • Bulking agents typically sugars or sugar alcohols such as sorbitol, sucrose, lactose or mannitol
  • Stabilisers typically water replacement sugars such as trehalose or sucrose that can protect the protein structure during freeze-drying.
  • Tonicity modifiers typically inorganic salts and amino acids (commonly glycine or arginine). These excipients are used to adjust osmolarity. Osmolarity (following re-constitution) is an important parameter of a protein formulation for therapeutic use.
  • Surfactants may be effective to prevent adsorption of proteins onto solid surfaces, agitation-induced aggregation and damage during freeze- drying.
  • aqueous solutions of proteins are often formulated in early stage development of a protein product during which the stability demands are not as strict as those for the final product.
  • aqueous protein solutions have to be stored strictly at 4 C. In most cases, structural degradation and loss of activity occur even at this temperature over a period of storage.
  • the stability of aqueous formulations can be improved by freezing, but in some cases the freeze-thaw cycle can contribute to the protein damage.
  • a typical aqueous protein solution is formulated in a conventional buffer, most commonly in phosphate buffer pH 6.8 - 7.3, although other buffers such as acetate, TRIS, carbonate or citrate are also used at certain pH ranges.
  • the formulations may also comprise one or more of tonicity modifiers, surfactants and stabilisers (see above).
  • the nature of additives in commercial protein formulations can vary.
  • the common feature of the commercial formulations of proteins both in dry and in aqueous format is the presence of a buffer.
  • a buffer is required to maintain the pH of the formulation close to a given value.
  • Many commercial proteins are formulated in phosphate buffer at pH close to 7. In some cases, other buffers and other pH can be used. Formulating at pH away from 7 is typically driven by the need to increase protein solubility, which can be achieved at pH away from the isoelectric point of the protein.
  • Acid- base equilibria relate to the exchange of protons (H + ; also referred to as hydrogen cations) between two chemical species. Whilst the species that is donating the proton is referred to as the acid, the species that is accepting the proton is referred to as the base. So, in the following reversible process, HA + B " ⁇ » HB + A "
  • HA acts as acid and B " acts as base.
  • HB acts as acid and A " acts as base.
  • K a which describes the equilibrium between the protonated and de-protonated form of a compound in aqueous solutions as follows: HX + H 2 O 4 » H 3 O + + X "
  • the pK a of any species is a function of temperature. Whilst in many cases, such as phosphate, citrate or acetate, the temperature dependence is small, some buffers (such as TRIS/HCI) exhibit change of pK a by as much as 0.03 unit per each 0 C.
  • the percentage of the protonated and de-protonated forms of a compound remains constant so long as the pH and the temperature are constant, this is a result of a dynamic equilibrium between the compound and surrounding molecules. In other words, there is a continuous dynamic exchange of protons between the acid-base species in a system while the overall protonation status of each species in the solution is maintained constant.
  • the species By donating or accepting protons in the pH range around its pK a the species acts as a buffer.
  • the presence of a buffer thus results in small changes of pH if either an acid or a base is added to the solution.
  • the choice of the appropriate buffer generally depends on the pH required.
  • the generally accepted rule is that the pK a of the buffer must be no more than one unit away from the required pH to act as an efficient buffer.
  • the pK a is within 0.5 units away from the required pH in order to maximise the buffering capacity of the species.
  • the pK a of the buffer is equal to the required pH of the solution. In this case, the proportion of the protonated form and the deprotonated form of the buffer are 50% respectively and its buffering capacity is utilised to the full extent. Such solution is then most efficiently protected against changes of pH both in the acid and in the alkaline direction.
  • EP1314437 discloses an aqueous composition comprising an antibody and histidine, at pH 7.1. This composition is said to be stable with respect to aggregation. Subsequent description suggests that, for use, a buffer should be added.
  • WO2007/003936 describes an aqueous system comprising a protein and one or more stabilising agents.
  • the stabilising agents have ionisable groups capable of exchanging protons with the protein and with the ionised product of water dissociation.
  • the ionisable groups include first groups that are positively charged when protonated and uncharged when deprotonated, and second groups that are uncharged when protonated and negatively charged when deprotonated.
  • the pH of the composition is within a range of protein stability that is at least 50% of the maximum stability of the protein with respect to the pH; alternatively, the pH of the composition is no more than 0.5 units more or less than the pH at which the composition has maximum stability with respect to pH.
  • the disclosure is based on the observation that, while there is invariably a range of pH values for which a composition is relatively stable, the presence of certain excipients is desirable. It is stated that a buffer may be added.
  • PCT/GB2008/000082 (unpublished at the first filing date of a patent application relating to the present invention) describes how to improve the stability of aqueous protein solutions.
  • the disclosure is based on the discovery that buffers having a pKa at or near the pH of the solution are undesirable, when considering the protein's stability with respect to pH. Rather, the key to the present invention is choice of the appropriate pH while minimizing the protein's ability to exchange hydrogen cations.
  • an aqueous system which comprises a protein and one or more additives, characterised in that
  • the system is substantially free of a conventional buffer, i.e a compound with pK a within 1 unit of the pH of the composition at the intended temperature range of storage of the composition;
  • the pH of the composition is set to a value at which the composition has maximum measurable stability with respect to pH;
  • the one or more additives are capable of exchanging protons with the protein and have pK a values at least 1 unit more or less than the pH of the composition at the intended temperature range of storage of the composition.
  • the storage stability of the protein can be increased substantially.
  • Storage stability can generally be enhanced further, possibly substantially, by use of additives having pKa between 1 to 5 pH units, preferably between 1 to 3 pH units, most preferably between 1.5 to 2.5 pH units of the pH of the aqueous composition at the intended temperature range of storage of the composition.
  • additives having pKa between 1 to 5 pH units, preferably between 1 to 3 pH units, most preferably between 1.5 to 2.5 pH units of the pH of the aqueous composition at the intended temperature range of storage of the composition.
  • the presence of these additives also improves the pH stability of the formulation and is generally preferred. Within the context of the present invention such additives are referred to as "displacement buffers".
  • the displacement buffers are further characterised by being either more than 90% de-protonated or more than 90% protonated at the pH of the aqueous composition.
  • the conventional buffers are both less than 90% de-protonated and less than 90% protonated, typically around 50% de-protonated and 50% protonated, at the pH of the aqueous composition.
  • the present invention is based on the realisation that the stability imparted to aqueous formulations by the technology described in
  • PCT/GB2008/00082 can be utilised in dry formulations intended primarily for therapeutic or diagnostic use, and are suitable for delivering proteins to the human or animal body.
  • the dry composition may be further formulated with one or more additives selected from excipients, bulking agents, stabilisers, disintegrants, binders and other therapeutic or diagnostic agents.
  • the dry composition may be shaped into a desired form, e.g. particles or powders, needles etc.
  • a dry composition of the invention is obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is that at which the protein is stable, wherein the or each displacement buffer has a pK a that is at least 1 unit greater or less than the pH of the aqueous composition, and wherein the aqueous composition is substantially free of a conventional buffer having a pK a that is within one pH unit of the pH of the aqueous composition.
  • the pH of the aqueous composition is preferably that at which the loss of the function and/or native structure of the protein in the dry state obtainable from such composition is minimal or at least near the minimal level, under defined conditions, such as storage at 4 0 C or storage at 25 0 C or storage at elevated temperatures.
  • a dry composition for use in therapy or diagnosis is obtainable by drying an aqueous composition comprising a protein and one or more displacement buffers, wherein the pH of the aqueous composition is such that the protein is stable, wherein the or each displacement buffer has a pKa that is at least 1 unit greater or less than the pH of the aqueous composition, and wherein the aqueous composition is substantially free of a conventional buffer having a pKa that is within one pH unit of the pH of the aqueous composition.
  • a composition of the invention may be defined as a dry composition for use in therapy or diagnosis, comprising a protein component which is a homogeneous mixture of a protein and one or more displacement buffers which, on reconstitution in water, gives an aqueous composition having a given pH, wherein the or each displacement buffer has a pKa that is at least 1 unit greater or less than the given pH, and wherein the mixture is substantially free of a conventional buffer having a pKa that is within one pH unit of the given pH.
  • a process for the preparation of a pharmaceutically acceptable composition comprises: (i) mixing a protein with one or more displacement buffers at a pH at which the protein is stable, wherein the or each displacement buffer has a pKa that is at least 1 unit greater or less than the pH of the aqueous composition, and wherein the aqueous composition is substantially free of a conventional buffer having a pKa that is within one pH unit of the pH of the aqueous composition.
  • Drying provides a "protein component" in which, together with any residual water, the protein and displacement buffer(s) may exhibit homogeneity at the molecular level. This degree of homogeneity may not be conferred to further additives in the solid phase.
  • the dry composition comprises, typically in admixture with at least one other discrete component, a homogeneous mixture of the protein and displacement buffer(s), and this mixture gives an aqueous composition having said pH, on reconstitution.
  • the pH of the aqueous composition following reconstitution is a key parameter of the dry compositions disclosed herein as it defines the protonation state of the additives used in the dry compositions.
  • a dry composition of the invention may be administered to a subject, to treat a condition for which the protein is known to be useful. Alternatively, administration may follow reconstitution.
  • the presence of the displacement buffer(s) serves to enhance the stability of the protein, typically with respect to temperature, e.g. so that cold storage can be avoided and/or to provide longer shelf-life.
  • the buffer(s) and other additives may also serve to enhance stability with respect to ionising radiation (used, for example, to sterilise the composition), further processing (e.g. drying of the aqueous composition, or milling, grinding, tableting or extrusion of the dry form), and after administration, where the protein may need to retain activity for a long period of time in the human body, depending on the release characteristics of the dosage form in which it is administered.
  • a dry composition of the invention may be prepared from an aqueous formulation of the type described in PCT/GB2008/000082 by a variety of procedures.
  • the composition will typically contain residual water, although the amount of water will be reduced, e.g. to less than 10%, preferably less than 5%, more preferably less than 2 or 3%, and often less than 1%, by weight of the dry composition.
  • Such a dry composition may be described below as a "solid dose system".
  • step (i) of the process of the invention will generally involve mixing the protein and one or more displacement buffers in water. However, the use of water is not essential. It is contemplated that any suitable solvent, e.g.
  • ethanol whether or not in admixture with water, may be used.
  • the invention further encompasses methods of making the solid dose systems. Suitable drying procedures include spray-drying, freeze-drying, air- drying, vacuum-drying, fluidised-bed drying, co-precipitation and super-critical fluid evaporation.
  • the invention is applicable to proteins of any molecular weight.
  • protein is used herein to encompass molecules or molecular complexes consisting of a single polypeptide, molecules or molecular complexes comprising two or more polypeptides and molecules or molecular complexes comprising one or more polypeptides together with one or more non-polypeptide moieties such as prosthetic groups, cofactors etc.
  • the invention relates to molecules having one or more biological activities of interest, which activity or activities are critically dependent on retention of a particular or native three- dimensional structure in at least a critical portion of the molecule or molecular complex.
  • proteins for use in the invention are protein or peptide hormones and growth factors (e.g. insulin, glucagon, human growth hormone, gonadotropin, human thyroid stimulation hormone, granulocyte colony stimulation factor), therapeutic enzymes (e.g. streptokinase, asparaginase, uricase), recombinant vaccines (e.g. hepatitis B vaccine, malaria vaccine, human papilloma vaccine, meningitis A vaccine, meningitis C vaccine, pertussis vaccine, polio vaccines), therapeutic antibodies (e.g.
  • protein or peptide hormones and growth factors e.g. insulin, glucagon, human growth hormone, gonadotropin, human thyroid stimulation hormone, granulocyte colony stimulation factor
  • therapeutic enzymes e.g. streptokinase, asparaginase, uricase
  • recombinant vaccines e.g. hepatitis B vaccine, malaria vaccine, human papilloma vaccine, meningitis
  • EGFR epidermal growth factor receptor
  • anti-HER2 monoclonal antibody anti-HER2 monoclonal antibody
  • anti-CD52 monoclonal antibody anti-CD20 monoclonal antibody
  • interferons and other therapeutic proteins such as erythropoietin, darbepoietin alpha (stimulating erythrocyte production), blood coagulation factors, such as factor VIII and factor IX or protein C.
  • the solid dose system may comprise a variety of additional components. Depending on their properties, their intended contribution to the system or their use, they may be incorporated in the solution to be dried or added to the dry system. Preferably, the components in the system are optimised to provide the best stability for the protein, initially in solution, and then additional components are added when the solution has been dried. Addition may comprise simple or intimate admixture, by any means known to those skilled in the art, e.g. dry mixing, or milling.
  • Additional components that may be used, typically added to the dry system, include other therapeutic agents as well as additives and excipients that will typically be chosen according to the intended use. These include bulking agents, binding agents, desiccants, controlled release agents and d is integrants. Examples are well known. Preferred excipient/bulking agents include sugars or polyalcohols such as sucrose, lactose, mannitol, polyethylene glycol, dextrans or sorbitol. Binding agents include substances such as sorbitol and polyvinyl pyrrolidone. Disintegrants are included to help a solid dose system disintegrate and may include celluloses or cros-povidone.
  • controlled release agents may be incorporated, e.g polylactide- co-glycolide (PLG), poly (lactic-co-glycolic) acid (PLGA), polycaprolactone, polyanhydride or a polyorthoester.
  • PLA polylactide- co-glycolide
  • PLA poly (lactic-co-glycolic) acid
  • polycaprolactone polyanhydride
  • polyorthoester e.g polylactide- co-glycolide (PLG), poly (lactic-co-glycolic) acid (PLGA), polycaprolactone, polyanhydride or a polyorthoester.
  • PLG polylactide- co-glycolide
  • PLGA poly (lactic-co-glycolic) acid
  • polycaprolactone polyanhydride
  • polyanhydride polyorthoester
  • Suitable additives include protein-stabilising agents such as protease inhibitors, chelating agents, anti-oxidants, preservatives, sugars and detergents. Such components may be added in step (i) of the process set out above.
  • additives selected from excipients, bulking agents, dessicants, disintegrants and binders. Any other protein, or another therapeutic or diagnostic agent may also be added at this stage.
  • the mixture that is obtained may be uniform, but would typically comprise, as discrete components, the 'protein component' that is homogeneous and obtainable from aqueous solution, and the one or more additives.
  • the aqueous composition (which may be the composition to be dried or the dry composition after reconstitution) contains less than 1 mM of conventional buffer.
  • the or each displacement buffer is preferably at a concentration of 1 mM to 1 M, preferably 2 to 200 mM, and most preferably from 5 to 10O mM.
  • dry compositions of the invention include those obtainable by drying an aqueous composition having a pH of about 5, comprising glucose oxidase and at least one additive selected from the group consisting of TRIS and lactate; by drying an aqueous composition having a pH of about 6.7, comprising catalase and at least one additive selected from the group consisting of TRIS, lysine and lactate; by drying an aqueous composition having a pH of about 8.3, comprising uricase and at least one additive selected from the group consisting of TRIS, lysine and lactate; by drying an aqueous composition having a pH of about 5, comprising Hepatitis B antigen and at least one additive selected from the group consisting of TRIS, histidine and lactate; or by drying an aqueous composition having a pH of about 6, comprising human growth hormone and at least one additive selected from the group consisting of TRIS, cytosine, purine and lactate.
  • the protein component and optionally also any additional component is capable of reconstitution in water. Reconstitution will result in an aqueous composition with a pH reflecting the protonation state of the excipients in the dry state.
  • the protonation state of the excipients is a key parameter of the compositions according to the present invention and it is therefore important to ensure minimal influence of the protonation conditions (i.e. pH) by the additional components, even if they are added to the system in the dry state subsequent to drying the protein component. So, the presence of the additional components will typically not cause a change in pH of more than 1 unit, preferably more than 0.5 unit, most preferably more than 0.2 unit, as measured in aqueous solution following reconstitution of the dry composition.
  • the invention also encompasses methods of delivering protein by providing a solid dose system as described herein and administering the system to a subject.
  • Administration can be mucosal, oral, topical, subcutaneous, intradermal, transdermal, intramuscular, intravenous, intranasal, intraocular or pulmonary, e.g. by inhalation.
  • Shaped compositions of the invention include particles, spherical or otherwise, e.g. for pulmonary delivery or formulations into tablets, pellets, implants, needles and fibres.
  • the solid dose system is sized and shaped for penetration of the epidermis and is suitable for ballistic delivery. A suitable size is in the range of 1-100 ⁇ m in diameter which allows penetration and delivery into the epidermis.
  • the solid dose system is shaped like a needle.
  • the stabilised, solution is dried and the dry stabilised material is mixed with selected binders and disintegrants.
  • This composition can then be formed into a needle shape directly by compression or by extruding a length of material that can then be cut into a short rod with a point on one end.
  • the advantage of having a needle shaped final formulation is that this can be pushed directly into the skin (dermal, subcutaneous and/or intramuscular delivery) with a simple mechanism. A suitable mechanism is described in US2006/0161111. Once in the skin the formulation dissolves, releasing the therapeutic or diagnostic agent. For this embodiment the final formulation must have sufficient physical strength that it can penetrate the tissue without a needle. Alternatively, rods of the final formulation can be cut and these can be inserted into the body using a needle and trocar system.
  • Alternative preferred embodiments of the delivery systems include uniform microspheres, preferably with a narrow size distribution. This is useful for pulmonary delivery and formulation into other dosage forms. It is also useful when control of the depth of penetration of the system is desirable. Such control may be useful, for example, for intradermal, intramuscular, subcutaneous or intravenous delivery or the targeting of vaccines to the basal layer of the epidermis, to bring antigen into proximity to the Langerhan's cells of the skin, to induce optimal immune responses.
  • Systems suitable for transmucosal delivery include mucoadhesive wafers, films or powders, lozenges for oral delivery, pessaries, and rings and other devices for vaginal or cervical delivery.
  • compositions suitable for gastrointestinal administration include powders, tablets, capsules and pills for ingestion and suppositories for rectal administration.
  • Compositions suitable for subcutaneous administration include various implants. Preferred implants are macroscopic discoid, spherical or cylindrical shapes for ease of insertion and may be either fast or slow release. Since the entire implant is dissolved in the body fluids, removal of the implant is not necessary. Furthermore, the implants do not contain synthetic polymers and are biodegradable.
  • compositions suitable for ocular administration include microsphere and macrosphere formulations and saline drops, creams and ointments containing these and round-ended shaped rods which fit comfortably in the lower conjunctival fornix beneath the lower eyelid.
  • Compositions suitable for administration by inhalation include po wder forms of the delivery systems.
  • the powders are of a particle size in the range 0.1 to 10 microns. More preferably, 0.5 to 5 microns, yet more preferably 1 to 4 microns, and most preferably 2.5 -3 microns.
  • Stabilised compositions in a dry form may be reconstituted and injected into the body with a standard needle and syringe.
  • the solutions that have stability of the protein optimised and then dried may still require bulking agents in the dry state in order that it is obvious to the user that there is material to be reconstituted.
  • bulking agents for example, microgramme quantities of a stabilised protein in a vial may not be obvious to the naked eye and so bulking agents will make it obvious that the vial has or has not been used.
  • Preferred solid dose systems/powders also contain an effective amount of a physiologically acceptable agent that reduces hygroscopicity to prevent substantial clumping, for instance, a 50% molar ratio of potassium sulphate.
  • a physiologically acceptable agent that reduces hygroscopicity to prevent substantial clumping, for instance, a 50% molar ratio of potassium sulphate.
  • Sodium sulphate and calcium lactate are the preferred salts with potassium sulphate being the most preferred.
  • Atomizers and vaporisers filled with the powders are also encompassed by the invention.
  • devices suitable for use in delivery of powders by inhalation including dry powder inhalers.
  • Devices suitable for use herein include those described in WO94/13271 , WO94/08552, WO93/09832 and US5239993.
  • compositions will often be more stable in a solid form and therefore it is possible to combine dry stabilised formulations of different proteins into one final dosage form providing not just better stability for the proteins but also better convenience for the patient.
  • the proteins may not be optimally combined for stability in an aqueous form or may require different buffers, but in a dry state they will not have the same potential for cross-reactivity. It will be understood that, where this specification makes reference to "a protein", more than one protein is included.
  • Example 1 glucose oxidase Dry samples of glucose oxidase were prepared by drying an aqueous solution of the enzyme (350 ⁇ g/mL) in glass vials adjusted to a particular pH in the presence of excipients. All compositions contained 100 mM NaCI (prior to drying). Drying was achieved under a stream of nitrogen at 30 0 C and subsequent incubation at atmospheric pressure in the presence of a desiccant. The vials were sealed and subjected to treatment at 70°C for 48 hours.
  • Dry samples of catalase were prepared by drying an aqueous solution of the enzyme (1 mg/mL) in glass vials adjusted to a particular pH in the presence of excipients. All compositions contained 100 mM NaCI (prior to drying). Drying was achieved under a stream of nitrogen at 30 0 C and subsequent incubation at atmospheric pressure in the presence of a desiccant. The vials were sealed and subjected to treatment at 65°C for 48 hours. Following the heat-treatment the samples were reconsitituted and analysed for remaining enzyme activity using the following procedure: 2 mL of hydrogen peroxide (30 mM in water) was added to 18 ml_ of PBS in a 125 ml. polypropylene pot.
  • the stability of catalase in the dry form was found to be dependent of the pH of the aqueous mixture from which the composition was dried.
  • the optimum stability was found to be around pH 7.5. It was shown that in the presence of conventional buffers applicable in this pH range, namely phosphate (pKa 7.1) and TRIS (pKa 8.1) activity recovery was considerably smaller compared with compositions in the absence of conventional buffers and in the presence of displaced buffer(s), such as histidine (pKal 6.1 , pKa2 9.0) or combination of maleate (pKa 6.1) and lysine (pKa 9.0).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition sèche destinée à être utilisée en thérapie ou diagnostic, que l'on peut obtenir par séchage d'une composition aqueuse comprenant une protéine et un ou plusieurs tampons de déplacement, par exemple TRIS, lactate, lysine et histidine, le pH de la composition aqueuse étant tel que la protéine est stable, chaque tampon de déplacement présentant un pKa qui est supérieur ou inférieur d'au moins une unité au pH de la composition aqueuse, ladite composition étant sensiblement exempte de tampon classique ayant un pKa compris dans une unité pH du pH de la composition aqueuse.
PCT/GB2009/050867 2008-07-16 2009-07-16 Stabilisation des proteines WO2010094906A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2726230A CA2726230A1 (fr) 2009-07-16 2009-07-16 Stabilisation des proteines
PCT/GB2009/050867 WO2010094906A1 (fr) 2009-07-16 2009-07-16 Stabilisation des proteines
EP20090785343 EP2341940A1 (fr) 2008-07-16 2009-07-16 Stabilisation des proteines
US12/851,328 US20110033549A1 (en) 2008-07-16 2010-08-05 Stabilisation of Proteins
US13/917,937 US20130280229A1 (en) 2008-07-16 2013-06-14 Stabilisation of Proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050867 WO2010094906A1 (fr) 2009-07-16 2009-07-16 Stabilisation des proteines

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/851,328 Continuation US20110033549A1 (en) 2008-07-16 2010-08-05 Stabilisation of Proteins
US13/851,328 Continuation US9266060B2 (en) 2008-07-16 2013-03-27 Dry scrubber system

Publications (1)

Publication Number Publication Date
WO2010094906A1 true WO2010094906A1 (fr) 2010-08-26

Family

ID=42077303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/050867 WO2010094906A1 (fr) 2008-07-16 2009-07-16 Stabilisation des proteines

Country Status (2)

Country Link
CA (1) CA2726230A1 (fr)
WO (1) WO2010094906A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204358A1 (fr) * 2013-06-18 2014-12-24 Zakharov Ivan Dmitrievich Médicament destiné à la prophylaxie et au traitement de la myopie pernicieuse et préparations pharmaceutiques sur la base de celui-ci

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506874B1 (en) * 1999-01-06 2003-01-14 Genentech, Inc. IGF-I variants
WO2007003936A1 (fr) * 2005-07-02 2007-01-11 Arecor Limited Systemes aqueux stables comprenant des proteines
WO2008084237A2 (fr) * 2007-01-11 2008-07-17 Arecor Limited Stabilisation de protéines
WO2009064838A1 (fr) * 2007-11-15 2009-05-22 Amgen, Inc. Préparation aqueuse de protéine de stimulation de l'érythropoïèse stabilisée par des antioxydants pour une administration par voie parentérale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506874B1 (en) * 1999-01-06 2003-01-14 Genentech, Inc. IGF-I variants
WO2007003936A1 (fr) * 2005-07-02 2007-01-11 Arecor Limited Systemes aqueux stables comprenant des proteines
WO2008084237A2 (fr) * 2007-01-11 2008-07-17 Arecor Limited Stabilisation de protéines
WO2009064838A1 (fr) * 2007-11-15 2009-05-22 Amgen, Inc. Préparation aqueuse de protéine de stimulation de l'érythropoïèse stabilisée par des antioxydants pour une administration par voie parentérale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204358A1 (fr) * 2013-06-18 2014-12-24 Zakharov Ivan Dmitrievich Médicament destiné à la prophylaxie et au traitement de la myopie pernicieuse et préparations pharmaceutiques sur la base de celui-ci

Also Published As

Publication number Publication date
CA2726230A1 (fr) 2010-08-19

Similar Documents

Publication Publication Date Title
US20210315961A1 (en) Stable formulations for parenteral injection of peptide drugs
ES2574761T3 (es) Formulaciones para el tratamiento de la diabetes
US6190699B1 (en) Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
CA2037884C (fr) Preparations stabilisees renfermant de la gonadotrophine
TW555569B (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
JP2000514811A (ja) タンパク質医薬の持続送達のための温度感受性ゲル
WO2012012460A1 (fr) Formulations de glucagon stables pour le traitement de l'hypoglycémie
TW201625294A (zh) 包含纖維蛋白溶酶原之醫藥組合物及其用途
CN103893744B (zh) 一种治疗糖尿病的药物制剂及其制备方法
JP2001524090A (ja) ペプチド、タンパク質および核酸を投与するための安定製剤形態
US20110033549A1 (en) Stabilisation of Proteins
WO2010094906A1 (fr) Stabilisation des proteines
KR100729954B1 (ko) Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
US20100028420A1 (en) Controlled release composition and process
KR20120129820A (ko) 의약 조성물 및 의약 조성물의 제조 방법
EP3225235B1 (fr) Formulations stables pour injection parentérale de médicaments peptidiques
US20200261584A1 (en) Stabilized protein gel preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009785343

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785343

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 7676/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2726230

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE